

KANSAS STATE BOARD OF PHARMACY ECONOMIC IMPACT STATEMENT

I. Summary of Proposed Regulations, Including Purpose. The Kansas State Board of Pharmacy (Board) is proposing new regulation K.A.R. 68-7-22 for the administration of the Kansas Pharmacy Practice Act, K.S.A. 65-1625 *et seq.*

It is the mission of the Board to ensure that all persons practicing pharmacy are properly licensed and registered, ensure compliance with Kansas statutes regarding proper compounding and dispensing of prescription drugs, maintenance of professional practice standards, and proper manufacture, distribution, and sale of prescription and nonprescription drugs, including controlled substances and poisons. In order to attain these goals, the Board is adding this regulation to comply with professional, healthcare, and safety norms.

K.A.R. 68-7-22. Collaborative Practice. This regulation provides definitions and standards for collaborative drug therapy management (CDTM) between pharmacists and physicians.

II. Federal Requirements. Though the Board makes every attempt to align Kansas rules and regulations with federal standards and practices, there are no federal requirements implicated by this regulation.

III. Anticipated Economic Impact on the Board. The Board anticipates that any economic impact will be related to general licensing record updates and document processing and storage. The regulation requires pharmacists update the Board with any new or updated collaborative practice agreements within five business days and report the status of any agreement biennially with their license renewal. Costs to the Board might appear in the form of staff time and are negligible in the scheme of current licensing staff functions.

IV. Anticipated Financial Impact Upon Other Governmental Agencies or Units. The Board does not anticipate that this regulation will have any financial impact upon other governmental agencies.

V. Anticipated Financial Impact Upon Small Employers and Private Citizens and Businesses. Pharmacists, physicians, and their respective private businesses engaged in CDTM may experience an economic impact. Additional time to coordinate the agreement as well as the CDTM practice may take additional time or resources, but the amount of any monetary impact is unknown. No other impact on private citizens or businesses is anticipated.

VI. Anticipated Economic Impact Upon Other Entities or Persons. There would be no negative impact on other entities or persons. There would be a positive impact on patient safety and welfare.

VII. Less costly or intrusive Methods that Were Considered, but Rejected, and the Reason for Rejection. The Board is not aware of any less costly or less intrusive methods to achieve the stated purpose and thus none were considered.